Celgene Notches A Needed Win As Acceleron-Partnered Luspatercept Succeeds In MDS

Celgene delivers positive top-line Phase III results for a key pipeline drug as luspatercept reduces the need for blood transfusions in patients with myelodysplastic syndromes. Partner Acceleron's stock soars ahead of a detailed data presentation later this year.